DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Lonafarnib is an investigational drug.
There have been 31 clinical trials for Lonafarnib. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2002.
The most common disease conditions in clinical trials are Hepatitis D, Hepatitis, and Hepatitis D, Chronic. The leading clinical trial sponsors are Schering-Plough, National Cancer Institute (NCI), and Eiger BioPharmaceuticals.
Recent Clinical Trials for Lonafarnib
|A Phase 3 Study of the Efficacy and Safety of Lonafarnib 50 mg / Ritonavir 100 mg With and Without Pegylated Interferon -Alfa-2a 180 mcg for 48 Weeks||Eiger BioPharmaceuticals||Phase 3|
|Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Phase 2|
|A Study of Lonafarnib With or Without Ritonavir in Patients With HDV||Eiger BioPharmaceuticals||Phase 2|